

Luis Paz-Ares

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3328009/publications.pdf>

Version: 2024-02-01

170
papers

37,307
citations

36691

53
h-index

7836

155
g-index

176
all docs

176
docs citations

176
times ranked

30967
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence of venous thromboembolism in patients with non-hematological cancer admitted for COVID-19 at a third-level hospital in Madrid. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 471-478.	1.0	8
2	Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options. <i>Journal of Clinical Oncology</i> , 2022, 40, 671-680.	0.8	59
3	Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1301-1311.	0.8	445
4	Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study. <i>Lung Cancer</i> , 2022, 167, 41-48.	0.9	18
5	RESILIENT part 1: A phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer. <i>Cancer</i> , 2022, , .	2.0	5
6	Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. <i>ESMO Open</i> , 2022, 7, 100408.	2.0	94
7	Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial. <i>ESMO Open</i> , 2022, 7, 100410.	2.0	10
8	Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer. <i>ESMO Open</i> , 2022, 7, 100399.	2.0	54
9	Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism. <i>Nature Medicine</i> , 2022, 28, 752-765.	15.2	30
10	Tunable gold nanorod/NAO conjugates for selective drug delivery in mitochondria-targeted cancer therapy. <i>Nanoscale</i> , 2022, 14, 8028-8040.	2.8	3
11	Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTALung platform. <i>Scientific Reports</i> , 2022, 12, 8342.	1.6	0
12	Analysis of patients with relapsed small cell lung cancer (SCLC) receiving single-agent lurbinectedin in the phase 3 ATLANTIS trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 8524-8524.	0.8	2
13	Abstract 1245: Comprehensive analysis of non-small cell lung cancer identifies molecular genotype-immunophenotype associations and candidate biomarkers predictive of response to immunotherapy. <i>Cancer Research</i> , 2022, 82, 1245-1245.	0.4	0
14	Abstract 3101: Evaluation of novel therapeutic strategies for KRAS mutated NSCLC patients using our own collections of PDX and PDX-derived organoids. <i>Cancer Research</i> , 2022, 82, 3101-3101.	0.4	0
15	Abstract 414: Comprehensive molecular characterization of mechanisms involved in primary resistance to EGFR tyrosine kinase inhibitors. <i>Cancer Research</i> , 2022, 82, 414-414.	0.4	0
16	Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 289-298.	0.5	35
17	Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 51-65.	5.1	356
18	Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). <i>Lung Cancer</i> , 2021, 151, 30-38.	0.9	30

#	ARTICLE	IF	CITATIONS
19	First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions. <i>ESMO Open</i> , 2021, 6, 100003.	2.0	21
20	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 198-211.	5.1	773
21	OA11.04 Lurbinectedin With Irinotecan in Relapsed Small Cell Lung Cancer. Results From the Expansion Stage of a Phase I-II Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, S127.	0.5	6
22	Combination treatment options for small-cell lung cancer – Authors' reply. <i>Lancet Oncology</i> , The, 2021, 22, e84.	5.1	1
23	First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1073-1082.	1.0	9
24	Response to: Bintrafusp Alfa in Second-Line Treatment of Patients With NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, e24.	0.5	0
25	Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer. <i>Future Oncology</i> , 2021, 17, 1165-1184.	1.1	2
26	Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC – an Update From the PACIFIC Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 860-867.	0.5	323
27	Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours. <i>ESMO Open</i> , 2021, 6, 100113.	2.0	17
28	Lurbinectedin in the treatment of relapsed small cell lung cancer. <i>Future Oncology</i> , 2021, 17, 2279-2289.	1.1	13
29	RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5258-5271.	3.2	23
30	Abstract CT154: Isatuximab (Isa) plus atezolizumab (Atezo) in patients (pts) with advanced malignancies: Results from a Phase 1/2 open-label multicenter study. , 2021, , .		1
31	Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1883-1892.	0.5	93
32	Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous Non-Small-Cell Lung Cancer in KEYNOTE-407. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100225.	0.6	13
33	PL02.03 Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, S844-S845.	0.5	22
34	First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. <i>ESMO Open</i> , 2021, 6, 100273.	2.0	91
35	MA16.06 Durvalumab ± Tremelimumab + Platinum-Etoposide in 1L ES-SCLC: Exploratory Analysis of HLA Genotype and Survival in CASPIAN. <i>Journal of Thoracic Oncology</i> , 2021, 16, S939.	0.5	8
36	458 – First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC). , 2021, 9, A486-A487.		13

#	ARTICLE	IF	CITATIONS
37	Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC Update from PACIFIC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 288-293.	0.5	328
38	Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus. <i>Clinical and Translational Oncology</i> , 2020, 22, 759-771.	1.2	11
39	Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors. <i>JAMA Oncology</i> , 2020, 6, 100.	3.4	68
40	Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2020, 22, 989-1003.	1.2	59
41	Lung Cancer and Microbiome. <i>Archivos De Bronconeumologia</i> , 2020, 56, 3-4.	0.4	6
42	Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. <i>Lancet Oncology</i> , The, 2020, 21, 271-282.	5.1	1,034
43	Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 271-280.	0.8	59
44	Impact of the COVID-19 outbreak on cancer patient flow and management: experience from a large university hospital in Spain. <i>ESMO Open</i> , 2020, 5, e000828.	2.0	17
45	LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN. <i>Annals of Oncology</i> , 2020, 31, S1212-S1213.	0.6	23
46	A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER. <i>Frontiers in Oncology</i> , 2020, 10, 578756.	1.3	36
47	Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study. <i>Lung Cancer</i> , 2020, 149, 46-52.	0.9	28
48	Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. <i>Cancer</i> , 2020, 126, 4867-4877.	2.0	69
49	Foreword to "The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms". <i>British Journal of Cancer</i> , 2020, 123, 1-2.	2.9	2
50	Summary of "The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms". <i>British Journal of Cancer</i> , 2020, 123, 36-36.	2.9	0
51	SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death. <i>European Journal of Cancer</i> , 2020, 135, 242-250.	1.3	74
52	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- β 2 and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1210-1222.	0.5	119
53	Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. <i>Lancet Oncology</i> , The, 2020, 21, 645-654.	5.1	247
54	Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. <i>Journal of Thoracic Oncology</i> , 2020, 15, 914-947.	0.5	119

#	ARTICLE	IF	CITATIONS
55	The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer. Expert Opinion on Drug Safety, 2020, 19, 233-242.	1.0	7
56	Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Annals of Oncology, 2020, 31, 798-806.	0.6	131
57	A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. Journal of Thoracic Oncology, 2020, 15, 1657-1669.	0.5	395
58	CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. European Journal of Cancer, 2020, 127, 160-172.	1.3	112
59	FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy. EBioMedicine, 2020, 53, 102683.	2.7	15
60	Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). Critical Reviews in Oncology/Hematology, 2020, 151, 102978.	2.0	79
61	Entrectinib in neurotrophic receptor tyrosine kinase fusion-positive (NTRK- fp) non-small cell lung cancer (NSCLC): integrated analysis of patients enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001. Pneumologie, 2020, 74, .	0.1	1
62	CASPIAN: OS results from a randomised Phase III study of first-line Durvalumab ± Tremelimumab plus chemotherapy in ED-SCLC: OS-Ergebnisse von CASPIAN, einer randomisierten Phase-III-Studie zur Erstlinientherapie von Durvalumab ± Tremelimumab + Chemotherapie beim Extensive Stage kleinzelligen Lungenkarzinom (ES-SCLC)., 2020, 74, .		0
63	Inmunoterapia en el c�ncer: grandes expectativas en el mundo de la oncolog�a, pero un motivo de preocupaci�n renal. Nefrologia, 2019, 39, 94-96.	0.2	1
64	Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Lancet Oncology, The, 2019, 20, 1109-1123.	5.1	193
65	Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients. Clinical Lung Cancer, 2019, 20, e601-e608.	1.1	38
66	PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN. Annals of Oncology, 2019, 30, v928-v929.	0.6	32
67	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 1655-1669.	5.1	418
68	Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations. JCO Precision Oncology, 2019, 3, 1-13.	1.5	11
69	A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. PLoS ONE, 2019, 14, e0221994.	1.1	23
70	Nivolumab plus Ipilimumab in Advanced Non�Small-Cell Lung Cancer. New England Journal of Medicine, 2019, 381, 2020-2031.	13.9	1,866
71	Durvalumab plus platinum�etoposide versus platinum�etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet, The, 2019, 394, 1929-1939.	6.3	1,274
72	First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light. Lung Cancer, 2019, 134, 245-253.	0.9	35

#	ARTICLE	IF	CITATIONS
73	Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. <i>Lung Cancer</i> , 2019, 134, 72-78.	0.9	24
74	FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy. <i>Journal of Thoracic Oncology</i> , 2019, 14, 641-655.	0.5	50
75	First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. <i>Journal of Clinical Oncology</i> , 2019, 37, 992-1000.	0.8	457
76	First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. <i>Lung Cancer</i> , 2019, 133, 10-19.	0.9	25
77	FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective. <i>Lung Cancer</i> , 2019, 131, 112-121.	0.9	12
78	First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1569-1579.	1.2	31
79	Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?. <i>Future Oncology</i> , 2019, 15, 1363-1383.	1.1	10
80	<p></p>First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 10463-10476.	0.9	56
81	Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. <i>Annals of Oncology</i> , 2019, 30, 290-296.	0.6	55
82	ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line. <i>Future Oncology</i> , 2019, 15, 231-239.	1.1	69
83	Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol. <i>Clinical Lung Cancer</i> , 2019, 20, e407-e412.	1.1	12
84	Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2019, 108, 120-128.	1.3	50
85	Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). <i>Annals of Oncology</i> , 2019, 30, 161-165.	0.6	60
86	Necitumumab for the treatment of advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 705-716.	1.1	28
87	CheckMate 817: Safety of flat-dose nivolumab (nivo) plus weight-based ipilimumab (ipi) for the first line (1L) treatment of advanced non-small cell lung cancer (NSCLC). <i>Pneumologie</i> , 2019, 73, .	0.1	0
88	P37...Phase 1 evaluation of bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF- β 2 and PD-L1, in cervical cancer. , 2019, , .		1
89	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2018, 93, 307-320.	1.4	22
90	Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. <i>New England Journal of Medicine</i> , 2018, 378, 2093-2104.	13.9	2,469

#	ARTICLE	IF	CITATIONS
91	Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. <i>Annals of Oncology</i> , 2018, 29, i10-i19.	0.6	449
92	Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2018, 19, 301-314.	1.1	7
93	Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 165-183.	0.5	134
94	Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR -Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results. <i>Clinical Lung Cancer</i> , 2018, 19, 213-220.e4.	1.1	13
95	Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab. <i>Oncologist</i> , 2018, 23, 1092-1102.	1.9	38
96	Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer. <i>European Respiratory Journal</i> , 2018, 51, 1702431.	3.1	32
97	Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. <i>Clinical Lung Cancer</i> , 2018, 19, 331-339.	1.1	15
98	Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. <i>Clinical Lung Cancer</i> , 2018, 19, e465-e479.	1.1	56
99	Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments. <i>Clinical Lung Cancer</i> , 2018, 19, 65-73.e7.	1.1	9
100	Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. <i>New England Journal of Medicine</i> , 2018, 379, 2342-2350.	13.9	2,150
101	Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2040-2051.	13.9	2,676
102	Durvalumab in NSCLC: latest evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591880415.	1.4	22
103	Lung Cancer with a High Tumor Mutational Burden. <i>New England Journal of Medicine</i> , 2018, 379, 1093-1094.	13.9	18
104	30 Immunotherapy in advanced NSCLC—from the “tsunami” of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT). <i>ESMO Open</i> , 2018, 3, e000298.	2.0	10
105	KRAS-Mutant non-small cell lung cancer: From biology to therapy. <i>Lung Cancer</i> , 2018, 124, 53-64.	0.9	232
106	Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. <i>Annals of Oncology</i> , 2018, 29, 1701-1709.	0.6	24
107	Abstract CT077: Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227. <i>Cancer Research</i> , 2018, 78, CT077-CT077.	0.4	11
108	Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy. <i>Clinical and Translational Oncology</i> , 2017, 19, 219-226.	1.2	3

#	ARTICLE	IF	CITATIONS
109	First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. <i>Lancet</i> , The, 2017, 389, 917-929.	6.3	919
110	Strategies to design clinical studies to identify predictive biomarkers in cancer research. <i>Cancer Treatment Reviews</i> , 2017, 53, 79-97.	3.4	80
111	Biological therapies in nonsmall cell lung cancer. <i>European Respiratory Journal</i> , 2017, 49, 1601520.	3.1	37
112	First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 2415-2426.	13.9	2,145
113	A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 108, 212-216.	0.9	35
114	Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung. <i>Journal of Clinical Oncology</i> , 2017, 35, 412-420.	0.8	237
115	Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 1919-1929.	13.9	3,261
116	Reflexiones sobre la implementación del cribado mediante tomografía computarizada de baja dosis en personas con riesgo elevado de padecer cáncer de pulmón en España. <i>Archivos De Bronconeumología</i> , 2017, 53, 568-573.	0.4	14
117	Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. <i>Lung Cancer</i> , 2017, 112, 181-187.	0.9	40
118	Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. <i>Annals of Oncology</i> , 2017, 28, 270-277.	0.6	425
119	Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement. <i>Clinical Lung Cancer</i> , 2017, 18, 667-674.e1.	1.1	13
120	Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 198-206.	1.2	22
121	Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib. <i>Frontiers in Medicine</i> , 2017, 4, 36.	1.2	11
122	Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. , 2017, 5, 71.		113
123	Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and Tj ETQq1 1 0784314 rgt /Over		
124	Current Challenges in Cancer Treatment. <i>Clinical Therapeutics</i> , 2016, 38, 1551-1566.	1.1	549
125	Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer. <i>Medical Oncology</i> , 2016, 33, 105.	1.2	3
126	Osimertinib in EGFR-mutant NSCLC: how to select patients and when to treat. <i>Lancet Oncology</i> , The, 2016, 17, 1622-1623.	5.1	2

#	ARTICLE	IF	CITATIONS
127	Clinicopathologic Features of Advanced Squamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1411-1422.	0.5	101
128	Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy. <i>Clinical Lung Cancer</i> , 2016, 17, 80-84.	1.1	45
129	Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20522-e20522.	0.8	7
130	A phase II multicenter, randomized, placebo-controlled, double-blind study of CC-486 plus pembrolizumab (pembro) vs pembro plus placebo (PBO) in previously treated patients (pts) with locally advanced/metastatic non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS9107-TPS9107.	0.8	1
131	Necitumumab for first-line treatment of advanced, squamous, non-small-cell lung cancer: a relevant step forward?. <i>Translational Lung Cancer Research</i> , 2016, 5, 95-7.	1.3	7
132	Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1745-1753.	0.5	100
133	A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 730-738.	3.2	265
134	Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. <i>JAMA Oncology</i> , 2015, 1, 149.	3.4	224
135	First-in-Human Dose Study of the Novel Transforming Growth Factor- β 2 Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma. <i>Clinical Cancer Research</i> , 2015, 21, 553-560.	3.2	199
136	Immunologic Checkpoint Blockade in Lung Cancer. <i>Seminars in Oncology</i> , 2015, 42, 402-417.	0.8	23
137	Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 1627-1639.	13.9	7,973
138	A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8009-8009.	0.8	27
139	A phase Ib study of abemaciclib in combination with multiple single agents in stage IV NSCLC.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8047-8047.	0.8	1
140	Exploratory analysis of safety by histology and efficacy in a nonsquamous NSCLC subgroup in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) vs DOC for second-line treatment of stage IV non-small-cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8055-8055.	0.8	6
141	Safety and efficacy of necitumumab continuation therapy: Subgroup analysis of phase 3 SQUIRE study.. <i>Journal of Clinical Oncology</i> , 2015, 33, e19024-e19024.	0.8	1
142	Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA109-LBA109.	0.8	13
143	Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA109-LBA109.	0.8	74
144	Elevated Levels of the Complement Activation Product C4d in Bronchial Fluids for the Diagnosis of Lung Cancer. <i>PLoS ONE</i> , 2015, 10, e0119878.	1.1	23

#	ARTICLE	IF	CITATIONS
145	Circulating tumor cells (CTCs) in patients with HER2-negative recurrent or metastatic breast cancer treated with eribulin as third-line therapy: ONSITE trial (OncoSur Analysis of the Treatment in Third) Tj ETQq1 1 0.784814 rgBT /Overlo	0.8	1
146	Clinical activity and cardiac tolerability of metronomic non-pegylated liposomal doxorubicin in heavily pre-treated patients with metastatic breast cancer: A single institucion experience.. Journal of Clinical Oncology, 2015, 33, e11570-e11570.	0.8	1
147	pERK as a new prognostic factor in resected, early-staged, non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, e18501-e18501.	0.8	0
148	Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2014, 15, 418-425.	1.1	31
149	Treatment for early-stage lung cancer: what next?. Lancet, The, 2014, 383, 1528-1530.	6.3	7
150	MicroRNA clusters: dysregulation in lung adenocarcinoma and COPD. European Respiratory Journal, 2014, 43, 1740-1749.	3.1	91
151	Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma. European Journal of Cancer, 2014, 50, 496-505.	1.3	26
152	Multiarmed, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling.. Journal of Clinical Oncology, 2014, 32, TPS8120-TPS8120.	0.8	3
153	MicroRNA-Dependent Regulation of Transcription in Non-Small Cell Lung Cancer. PLoS ONE, 2014, 9, e90524.	1.1	65
154	Accurate Identification of ALK Positive Lung Carcinoma Patients: Novel FDA-Cleared Automated Fluorescence In Situ Hybridization Scanning System and Ultrasensitive Immunohistochemistry. PLoS ONE, 2014, 9, e107200.	1.1	58
155	Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Investigational New Drugs, 2012, 30, 729-740.	1.2	36
156	GAIN-(L): Efficacy and biomarker findings of RG7160 (GA201), a novel, dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with first-line cisplatin and pemetrexed in metastatic nonsquamous NSCLC.. Journal of Clinical Oncology, 2012, 30, 7544-7544.	0.8	0
157	Clinical outcomes in nonâ€“smallâ€“cell lung cancer patients with <i>EGFR</i> mutations: pooled analysis. Journal of Cellular and Molecular Medicine, 2010, 14, 51-69.	1.6	126
158	Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). Annals of Oncology, 2010, 21, 195-198.	0.6	41
159	Between Bench and Bed Side: PI3K Inhibitors. Current Molecular Pharmacology, 2010, 3, 79-90.	0.7	1
160	SEOM guidelines for the management of non-small-cell lung cancer (NSCLC). Clinical and Translational Oncology, 2009, 11, 284-289.	1.2	14
161	Inhibiting PI3K as a therapeutic strategy against cancer. Clinical and Translational Oncology, 2009, 11, 572-579.	1.2	28
162	Safety and efficacy of AMG 655 in combination with paclitaxel and carboplatin (PC) in patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology, 2009, 27, e19048-e19048.	0.8	20

#	ARTICLE	IF	CITATIONS
163	Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2008, 98, 1608-1613.	2.9	155
164	Phase II Study of Trabectedin in Pretreated Patients with Advanced Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2007, 6, 522-528.	1.0	13
165	Phase II study of irinotecan (cpt-11) and cisplatin (cddp) regimen (IP) with concurrent thoracic radiotherapy (TRT) in limited-stage small cell lung cancer (LS-SCLC). <i>Journal of Clinical Oncology</i> , 2006, 24, 7084-7084.	0.8	3
166	A phase I/IIA pharmacokinetic (PK) and serial skin and tumor pharmacodynamic (PD) study of the EGFR irreversible tyrosine kinase inhibitor EKB-569 in combination with 5-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) (FOLFIRI regimen) in patients (pts) with advanced colorectal cancer (ACC). <i>Journal of Clinical Oncology</i> , 2004, 22, 3543-3543.	0.8	6
167	A phase I/IIA pharmacokinetic (PK) and serial skin and tumor pharmacodynamic (PD) study of the EGFR irreversible tyrosine kinase inhibitor EKB-569 in combination with 5-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) (FOLFIRI regimen) in patients (pts) with advanced colorectal cancer (ACC). <i>Journal of Clinical Oncology</i> , 2004, 22, 3543-3543.	0.8	12
168	Procalcitonin (PCT) as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. <i>Journal of Clinical Oncology</i> , 2004, 22, 8037-8037.	0.8	0
169	Procalcitonin (PCT) as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. <i>Journal of Clinical Oncology</i> , 2004, 22, 8037-8037.	0.8	0
170	Envolving treatment of fever and neutropenia in cancer patients. , 2002, 4, 297-307.		0